|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 122.89 AUD | -2.10% |
|
+0.89% | -28.82% |
| 07-08 | Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine | RE |
| 07-03 | Australian shares log best week in 3 as Fed-hike bets cool; banks, miners lead | RE |
Company Valuation: CSL Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 97,314 | 89,299 | 89,052 | 95,184 | 76,024 | 40,936 | - | - |
| Change | - | -8.24% | -0.28% | 6.89% | -20.13% | -46.15% | - | - |
| Enterprise Value (EV) 1 | 101,307 | 88,520 | 99,731 | 105,710 | 85,005 | 49,785 | 49,006 | 48,353 |
| Change | - | -12.62% | 12.66% | 5.99% | -19.59% | -41.43% | -1.57% | -1.33% |
| P/E | 41x | 38.6x | 40.8x | 36.1x | 25.4x | -46x | 28.5x | 13.1x |
| PBR | 11.6x | 6.13x | 5.64x | 5.48x | 3.93x | 2.51x | 2.5x | 2.28x |
| PEG | - | -4.91x | -7.25x | 1.8x | 1.9x | 0x | -0x | 0x |
| Capitalization / Revenue | 9.44x | 8.45x | 6.69x | 6.43x | 4.89x | 2.66x | 2.62x | 2.52x |
| EV / Revenue | 9.83x | 8.38x | 7.49x | 7.14x | 5.46x | 3.23x | 3.13x | 2.98x |
| EV / EBITDA | 27.2x | 24.6x | 25.6x | 22.3x | 16.5x | 9.56x | 9.47x | 8.91x |
| EV / EBIT | 32.4x | 30.2x | 32.5x | 27.7x | 19x | 11.2x | 11x | 10.4x |
| EV / FCF | 41.8x | 57.1x | 72.6x | 55.2x | 29.1x | 17.7x | 16.3x | 16.7x |
| FCF Yield | 2.39% | 1.75% | 1.38% | 1.81% | 3.44% | 5.65% | 6.15% | 5.99% |
| Dividend per Share 2 | 2.22 | 2.22 | 2.36 | 2.64 | 2.92 | 2.851 | 2.925 | 3.085 |
| Rate of return | 1.04% | 1.2% | 1.28% | 1.34% | 1.86% | 3.34% | 3.42% | 3.61% |
| EPS 2 | 5.21 | 4.8 | 4.53 | 5.45 | 6.17 | -1.858 | 3.001 | 6.512 |
| Distribution rate | 42.6% | 46.3% | 52.1% | 48.4% | 47.3% | -153% | 97.5% | 47.4% |
| Net sales 1 | 10,310 | 10,562 | 13,310 | 14,800 | 15,558 | 15,392 | 15,635 | 16,244 |
| EBITDA 1 | 3,720 | 3,596 | 3,900 | 4,750 | 5,151 | 5,208 | 5,172 | 5,424 |
| EBIT 1 | 3,130 | 2,927 | 3,069 | 3,812 | 4,468 | 4,464 | 4,447 | 4,652 |
| Net income 1 | 2,375 | 2,255 | 2,194 | 2,642 | 3,002 | -893.6 | 1,183 | 3,112 |
| Net Debt 1 | 3,993 | -778.6 | 10,679 | 10,526 | 8,981 | 8,849 | 8,070 | 7,417 |
| Reference price 2 | 213.82 | 185.38 | 184.61 | 196.96 | 157.01 | 85.48 | 85.48 | 85.48 |
| Nbr of stocks (in thousands) | 455,126 | 481,706 | 482,372 | 483,253 | 484,212 | 478,912 | - | - |
| Announcement Date | 17/08/21 | 16/08/22 | 14/08/23 | 12/08/24 | 18/08/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -46.01x | 3.23x | 9.56x | 3.34% | 40.94B | |
| 17.35x | 3.77x | 10.12x | 0.59% | 67.61B | |
| 25.62x | 5.26x | 15.43x | 0.62% | 51.6B | |
| 34.6x | 11.72x | 22.41x | -.--% | 43B | |
| 30.35x | 3.47x | 10.97x | -.--% | 29.4B | |
| -7.88x | 11.31x | -6.94x | -.--% | 27.09B | |
| 37.89x | 3.25x | 9.81x | -.--% | 23.32B | |
| 62.11x | 6.31x | 43.4x | -.--% | 19.92B | |
| 26.16x | 5.4x | 14.45x | -.--% | 16.91B | |
| -39.16x | 18.25x | -55.41x | -.--% | 16.84B | |
| Average | 14.10x | 7.20x | 7.38x | 0.45% | 33.66B | |
| Weighted average by Cap. | 13.91x | 6.45x | 10.02x | 0.62% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CSL Stock
- Valuation CSL Limited
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
